VERU INC.
Close on Oct 19, 2026
- Market cap
- $53.25M
- P/E (TTM)
- –
- Dividend yield
- –
About VERU
Pharmaceutical Preparations, SIC 2834
Veru Inc. is a clinical-stage biopharmaceutical company that develops treatments for cardiometabolic and inflammatory diseases. The firm focuses on two drug candidates: enobosarm and sabizabulin. Enobosarm is an oral selective androgen receptor modulator designed to preserve lean muscle tissue and increase fat reduction in individuals undergoing weight-loss therapy with GLP-1 receptor agonists. Sabizabulin is an oral microtubule disruptor intended to diminish vascular inflammation in patients with atherosclerotic cardiovascular conditions. Through these investigational programs, the company targets overweight individuals, older adults with obesity at risk of muscle loss, and patients diagnosed with coronary artery disease.
The company operates as a Wisconsin corporation. Following the divestment of its commercial internal condom business, which previously included operating entities in the United Kingdom and Malaysia, its current activities focus on clinical research programs within the United States. Its clinical scale includes multicenter studies involving several hundred trial participants across its metabolic and cardiovascular programs.
Summary of the business section of VERU's latest annual report, written by StockData.
Company profile
Company
- Legal name
- VERU INC.
- Founded
- 1971
- Headquarters
- Miami, FL
- Address
- 2916 N. Miami Avenue, Suite 1000 33127
- Phone
- (312) 595-9123
- Website
- verupharma.com
- Employees
- 20, Sep 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Wisconsin
- Fiscal year ends
- September 30
- Auditor
- Cherry Bekaert LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- VERU
- Exchange
- Nasdaq
- IPO date
- Feb 11, 1999
- Shares outstanding
- 17M, Aug 6, 2026
- Public float
- $64.10M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Aug 12, 2025; 1-for-10 reverse, Aug 11, 2025
- SEC CIK
- 863894
- CUSIP
- 92536C202
- ISIN
- US92536C2026
- LEI
- 529900ER63TFLEIJV631
- EIN
- 39-1144397
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Harry Fisch | Chief Corporate Officer, Director | 8,013,832 |
| Mitchell Shuster Steiner | President and CEO, Director | 7,086,709 |
| K. Gary Barnette | Chief Scientific Officer | 2,300 |
| Michele Greco | Chief Admin Officer and CFO | 96,178 |
| Michael L. Rankowitz | Director | 250,000 |
| Lucy Lu | Director | 9,800 |
| Grace Hyun | Director | 14,790 |
| Loren Mark Katzovitz | Director | 224,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mitchell Steiner | $1.65M | $1.38M | $855.21K | $3 | – |
| FY2024 Mitchell Steiner | $1.98M | $1.83M | $925.69K | $7 | – |
| FY2023 Mitchell Steiner | $4.71M | -$5.95M | $1.62M | $6 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 1, 2025, the Company had 20 full-time employees, all of whom are located in the U.S.”
Corporate history
Events identified from SEC filings